Vaccines against bacterial zoonoses

References

1. Hambleton P., Turnbull P. C. B. Anthrax vaccine development: a continuing story. In Mizrahi A. (ed) Bacterial vaccines Adv Biotechnol Processes; 1990; 13105–122
   [Google Scholar]
2. Shlyakov E. N., Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 199412727–730
   [Google Scholar]
3. Brachman P. S., Gold H., Plotkin S. A., Fekerty F. R., Werrin M., Ingraham N. R. Field evaluation of a human anthrax vaccine. Am J Public Health 1962; 52:632–645
   [Google Scholar]
4. Ivins B. E., Fellows P. F., Nelson G. O. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine 1994; 12:872–874
   [Google Scholar]
5. Leppla S. H. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eukaryotic cells. In Greengard P. (ed) Advances in cyclic nucleotide and protein phosphorylation research Orlando: Academic Press; 1984103–116
   [Google Scholar]
6. Klimpel K. R., Arora N., Leppla S. H. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol 1994; 13:1093–1100
   [Google Scholar]
7. Ivins B., Fellows P., Pitt L. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 1995; 13:1779–1794
   [Google Scholar]
8. Coulson N. M., Fulop M., Titball R. W. Bacillus anthracis protective antigen expressed in Salmonella typhimurium SL 3261, affords protection against spore challenge. Vaccine 1994; 12:1395–1401
   [Google Scholar]
9. Lopez Merino A., Asselineau J., Serre A., Roux J., Bascoul S., Lacave C. Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances. Infect Immun 1976; 13:311–321
   [Google Scholar]
10. Dranovskaya E. A. New approaches to brucellosis vaccination of people with high risk of infection. In Tumbay E., Hilmi S., Ang O. (eds) Brucella and brucellosis in man and animals Turkish Microbiology Society 1991; 1687–100 Ege University Press; Izmir:
    [Google Scholar]
11. Schurig G. G., Roop R. M., Bagchi T., Boyle S., Buhrman D., Sriranganathan N. Biological properties of RB51. A stable strain of Brucella abortus . Vet Microbiol 1991; 28:171–188
    [Google Scholar]
12. Drazek E. S., Young H. H., Crawford R. M., Hadfield T. L., Hoover D. L., Warren R. L. Deletion of pur E attenuates Brucella melitensis 16 M for growth in human monocyte-derived macrophages. Infect Immun 1995; 63:3277–3301
    [Google Scholar]
13. Cheville N. F., Olsen S. C., Jensen A. E. Bacterial persistence and immunity in goats vaccinated with a pur E deletion mutant or the parental 16 M strain of Brucella melitensis . Infect Immun 1996; 64:2431–2439
    [Google Scholar]
14. Oliveira S. C., Splitter G. A. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 1996; 14:959–962
    [Google Scholar]
15. Jacques I., Olivier-Bemardin V., Dubray G. Induction of antibody and protective responses in mice by Brucella O-polysaccharide-BSA conjugate. Vaccine 1991; 9:896–900
    [Google Scholar]
16. Russel P., Eley S. M., Hibbs S. E., Manchee R. J., Stagg A. J., Titball R. W. A comparison of Plague Vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 1995; 13:1551–1556
    [Google Scholar]
17. Meyer K. F. Effectiveness of live or killed plague vaccines in man. Bull World Health Organ 1970; 42:653–666
    [Google Scholar]
18. Andrews G. P., Heath D. G., Anderson G. W., Welkos S. L., Fried-lander A. M. Fraction-1 capsular antigen (FI) purification from Yersinia pestis C092 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 1996; 64:2180–2187
    [Google Scholar]
19. Leary S. E.C., Williamson E. D., Griffin K. F., Russell P., Eley S. M., Titball R. W. Active immunization with recombinant V antigen for Yersinia pestis protects mice against plague. Infect Immun 1995; 63:2854–2858
    [Google Scholar]
20. Oyston P. C.F., Williamson E. D., Leary S. E.C., Eley S. M., Griffin K. F., Titball R. W. Immunization with live recombinant Salmonella typhimurium aroA producing FI antigen protects against plague. Infect Immun 1995; 63:563–568
    [Google Scholar]
21. Oyston P. C.F., Russell P., Williamson E. D., Titball R. W. An aro A mutant of Yersinia pestis is attenuated in guinea-pigs, but virulent in mice. Microbiology 1996; 142:1847–1853
    [Google Scholar]
22. Keller D., Koster F. T., Marks D. H., Hosbach P., Erdile L. F., Mays J. P. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 1994; 271:1764–1768
    [Google Scholar]
23. Eldelman R. The Sixth International Conference on Lyme borreliosis: progress on the development of Lyme disease vaccines. Vaccine 1995; 13:133–135
    [Google Scholar]
24. Homick R. B., Eigelsbach H. T. Aerogenic immunization of man with live tularaemia vaccine. Bact Rev 1966; 30:532–538
    [Google Scholar]
25. Fulop M., Manchee R., Titball R. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularaemia. Vaccine 1995; 13:1220–1225
    [Google Scholar]
26. Ackland J. R., Worswick D. A., Marmion B. P. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vac (CSL) 1985-1990. Med J Aust 1994; 160:704–708
    [Google Scholar]
27. Kazar J., Brezhina R., Palanova A., Tvrda B., Schramek S. Immunogenicity and reactogenicity of a Q fever chemovaccine in persons professionally exposed to Q fever in Czechoslovakia. Bull World Health Organ 1982; 60:389–394
    [Google Scholar]
28. Genig V. A. Experience on mass immunization of human beings with the M-44 live vaccine against Q-fever. Report 2. Skin and oral routes of immunization. Vopr Virusol 1965; 6:703–707
    [Google Scholar]
29. Chen T. Z. Development and present status of leptospiral vaccine and technology of production of the vaccine in China. Ann Immunol Hung 1986; 26:125–151
    [Google Scholar]